Institute Of Hematology & Blood Diseases Hospital, China

This early-phase trial tests a two-step CAR-T cell therapy for people with relapsed or refractory acute myeloid leukemia (AML), a type of blood cancer that has not responded to standard treatments. Ten participants will receive an infusion of dual-target CAR-T cells followed by a…

This study tests a milder chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant for people with blast phase chronic myeloid leukemia, an advanced and hard-to-treat form of the disease. The goal is to see if this gentler approach can help patients l…

This study tests a new scoring system that uses the body's immune recovery to decide how long patients should take antiviral medicine after a stem cell transplant. The goal is to prevent a common virus called CMV from coming back when the medicine stops. About 1,100 transplant re…

This early-phase study tests a new type of CAR-T cell therapy called Sup19 in 9 adults with B-cell blood cancers (like leukemia or lymphoma) that either stopped responding to previous CD19-targeted treatments or have low levels of the CD19 protein. The main goal is to check safet…

This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. About 27 newly diagnosed adults will receive the drugs to see how well they shrink tumors and contro…

This early-stage study tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses specially modified immune cells to attack the cancer. The main goals are to check safety, find the b…

This study tests whether adding venetoclax to azacitidine as maintenance therapy helps keep acute myeloid leukemia (AML) in remission longer. About 788 people aged 14 to 74 who are already in remission after initial treatment will be randomly assigned to receive either azacitidin…

This study tests whether the drug gecacitinib can help people with myelofibrosis (a serious bone marrow disorder) who are getting a stem cell transplant. About 39 adults will receive the drug before, during, and after their transplant. The goal is to see if it reduces serious com…

This early-phase trial tests a new treatment called CD7 CAR-T cell therapy in 10 children with high-risk T-cell leukemia or lymphoma. After standard chemotherapy puts the cancer into remission, the child's own immune cells are collected, modified to better attack cancer cells, an…

This study tests whether a three-drug combination (VAG) works better than standard chemotherapy for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 people aged 14 to 74 will be randomly assigned to receive either the new triple-drug reg…

This study is for adults with a rare leukemia that is hard to treat. It combines targeted immune drugs with chemotherapy to see if it can help patients live longer and achieve remission. About 50 people will take part across multiple hospitals in China.

This study tests whether the drug ivarmacitinib can prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a stem cell transplant from a half-matched donor. aGVHD occurs when donor immune cells attack the patient's body. The study will measure h…

This early-phase study tests a new type of CAR-T cell therapy (CD19X) in 3 people with relapsed or refractory large B-cell lymphoma, a blood cancer that has not responded to standard treatments. The main goal is to check safety, looking for side effects like cytokine release synd…

This study compares two first-line treatments for severe aplastic anemia, a condition where the bone marrow fails to produce enough blood cells. It will involve 116 patients aged 14-70 who lack a fully matched donor. One group receives a stem cell transplant from a half-matched f…

This study tests a new drug called gecacitinib in 33 adults with chronic graft-versus-host disease (cGVHD) that hasn't improved with steroids. The goal is to find a safe dose and see if it can control the disease. Participants must have had a stem cell transplant and have active …

This early-phase study tests a time-limited treatment for Waldenström macroglobulinemia, a rare blood cancer. About 21 adults will receive a sequence of ibrutinib, bendamustine, and rituximab over a few months, then stop. The goal is to find a safe dose and see if the cancer can …

This study looks at 112 people with immune thrombocytopenia (ITP) whose platelets didn't improve with standard-dose rhTPO. After a two-week break, they will either get a double dose of rhTPO or switch to eltrombopag. The goal is to see which approach better raises platelet counts…

This study tests a new three-drug combination (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combo can safely improve remission rates. Participants will receive …

This early-phase study tests whether metformin, a common diabetes medicine, can reduce levels of a specific gene mutation (DNMT3A R882) in 30 adults with acute leukemia who are in remission. Participants take metformin pills for 6 months. The goal is to see if the mutation drops …

This study tests a new drug (JAK1 inhibitor) combined with strong immune-suppressing therapy for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The trial has two parts: first, a small safety test in patients who didn't …

This study tests whether giving focused radiation (SBRT) before a stem cell transplant can improve outcomes for adults with blood cancers that have spread outside the bone marrow. About 20 participants aged 18-60 will receive the radiation followed by a donor stem cell transplant…

This early-stage study tests a new treatment called CT1390B for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and see if it helps control the disease. About 18 participant…

This early-phase study tests a new CAR-T cell treatment called CT1195E in 30 adults with relapsed or refractory B-cell lymphoma or leukemia. The main goals are to check safety, find the best dose, and see how well the therapy works. Participants receive a single infusion of their…

This early study tests whether probiotics made from the patient's own or their donor's gut bacteria can improve intestinal health in people who develop acute graft-versus-host disease (aGVHD) after a stem cell transplant. Ten adults over age 50 will take probiotic capsules and be…

This study tests a new combination of chemotherapy drugs before a cord blood transplant in 44 patients aged 60-69 with blood cancers. The goal is to see if this approach lowers the risk of death from transplant complications within 180 days. Participants receive the transplant an…

This early-phase study tests a new treatment called IASO104 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main goal is to check s…

This early-stage study tests a new drug called QI-019B in 24 adults with multiple myeloma that has returned or not responded to at least two prior treatments. The main goal is to check safety and side effects, while also seeing if the drug can shrink the cancer. It is a single-ce…

This early-stage study tests a new treatment called CT1194D CAR-T cells for patients whose B-cell blood cancers have returned or not responded to standard therapy. The main goals are to check the treatment's safety and find the best dose. About 20 adults aged 18-75 will take part…

This study tests whether a combination of two drugs (olverembatinib and inotuzumab ozogamicin) can eliminate leftover leukemia cells in adults with a certain type of acute lymphoblastic leukemia (Ph+ ALL) who still have detectable disease after initial treatment. The goal is to a…

This study tests a drug called daratumumab in people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it is safe and can help the body make more blood cells. About 37 participants will receive multiple doses, and researchers will check for…

This study tests a drug called CM336 (a BCMA/CD3 bispecific antibody) as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. The goal is to turn minimal residual disease (MRD) from positive to negative, meaning no detectable cancer ce…

This study tests whether adding all-trans retinoic acid to avatrombopag works better than avatrombopag alone for adults with immune thrombocytopenia (ITP) who didn't improve with first treatment. About 248 participants will take the drugs for up to 24 weeks, then taper off, and b…

This study tests a new medicine called zuberitamab for people who develop an EBV infection after a stem cell transplant. EBV can cause a serious condition called PTLD, which can be fatal if not treated. The drug targets infected cells to clear the virus and prevent complications.…

This early-phase trial tests a new treatment called SL4903 for people with multiple myeloma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goal is to check safety and find the b…

This early-phase trial tests an experimental therapy called JY509, made from donor natural killer (NK) cells, in 18 children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The goal is to see if these immune cells are safe and can h…

This early-phase study tests a new treatment called CY-219 CAR-T cells for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals are to check safety and…

This early study tests a one-time treatment called KL003 in 3 people with severe sickle cell disease. The treatment uses the patient's own blood stem cells, which are modified in a lab to produce healthy red blood cells. The goal is to see if the modified cells can safely and suc…

This early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma. Ten adults whose cancer has not responded to multiple prior treatments will receive the antibody first…

This early study tests a new treatment called CD19 UCAR-T cell therapy for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goals are t…

This early study tests a new injection called SYS6055 in 86 adults with B-cell blood cancers (like leukemia or lymphoma) that returned or didn't respond to standard treatments. The main goals are to check safety, find the best dose, and see if it shrinks tumors. It's a first step…

This study tests a combination of three drugs (zanubrutinib, a reduced dose of bendamustine, and a CD20 antibody) in 43 people with untreated Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if this approach can achieve a very good partial response or better…

This study tests if luspatercept can improve anemia in 20 adults with blood cancers who had a stem cell transplant. The goal is to reduce the need for red blood cell transfusions. Participants must be 18-60 and have low hemoglobin after transplant.

This study looks at whether Polyene Phosphatidylcholine injection can prevent or treat liver injury caused by chemotherapy in adults with blood cancers like leukemia or lymphoma. Researchers will review medical records of 1000 patients to see how well the drug works and if it is …

This early-stage study tests a treatment called GC012F in 9 adults with difficult-to-treat rheumatoid arthritis. The therapy uses a person's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety and measure how long the cells…

This early-stage trial tests a new treatment using donor immune cells (CAR-γδT cells) designed to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 participants. If…

This study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior treatment. The first part finds the safest dose, and the second part checks how well the combo…

This study tests a combination of two drugs, mosunetuzumab and zeprumetostat, in about 80 people with follicular lymphoma, a type of blood cancer. Participants include those with newly diagnosed high-risk or low-tumor-burden disease, as well as those whose cancer has returned or …

This early-stage trial tests whether giving a bispecific antibody (GPRC5D/CD3) before CAR-T cell therapy can improve outcomes for adults with relapsed/refractory multiple myeloma, a blood cancer that has stopped responding to standard treatments. About 20 participants will receiv…

This study is for adults aged 14 to 60 with newly diagnosed Ph-negative acute lymphoblastic leukemia (ALL), a fast-growing blood cancer. Researchers are testing a treatment plan that combines a pediatric-style chemotherapy with the targeted drug venetoclax and immunotherapy. The …

This early study tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment is a type of CAR-T therapy that works inside the body to help immune cells attack cancer. About 12 adults aged 18-7…

This early-stage study is testing a new type of CAR-T cell therapy, called BAFF-R CAR-T, for people with B-cell lymphomas that have come back or haven't responded to other treatments. Researchers will give the therapy at different doses to about 20 participants to check how safe …

This early-stage study tests whether specially trained immune cells from a donor can prevent Epstein-Barr virus (EBV) infection in people who have received a stem cell transplant. About 9 to 18 high-risk participants will receive these cells and be monitored for side effects and …

This study looks at how the antifungal drug liposomal amphotericin B behaves in 10 critically ill adults with severe fungal infections who are also receiving plasma exchange therapy. The goal is to understand how plasma exchange affects drug levels, so doctors can give the right …

This study will follow 1,000 adults who have received a stem cell transplant to see how often they pick up a hard-to-treat bacteria called MBL-CRE in the anal area. Researchers want to learn who gets infected, what factors raise the risk, and how the bacteria resist antibiotics. …

This study collects information from medical records of about 500 patients with immune thrombocytopenia (ITP) to see what treatments they received and how well they worked. It includes both treated and untreated patients aged 6 and older. The goal is to learn about current treatm…

This study looks for proteins in the blood that can help doctors predict if a patient will develop chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Researchers will analyze blood samples from 1500 transplant recipients to build a model that combines these p…

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection (In Vivo CAR-T) in Patients with Relapsed/Refractory Autoimmune Hemolytic Anemia